Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications ROCHESTER, Minn., July 20, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today the dosing of the first patient in a Phase 2 clinical trial to evaluate its investigational oncolytic virus...